DeckTherapeutics appoints Professor Yechezkel Barenholz, PhD to its Board of Directors
DeckTherapeutics today announced that it has appointed Dr. Yechezkel (Chezy) Barenholz to its Board of Directors. Professor Barenholz is a professor emeritus of biochemistry and cancer research at the Hebrew University‐Hadassah Medical School, Jerusalem, and a recognized expert in the field
DeckTherapeutics appoints Dr. Larry Gold to the Board of Directors
DeckTherapeutics today announced that it has appointed Dr. Larry Gold to its Board of Directors. Dr. Gold is an internationally recognized scientist whose research at the University of Colorado Boulder has spawned numerous discoveries and commercially successful biotechnology patents. Dr. Gold is
DeckTherapeutics’ technology platform featured in The Wall Street Journal
Founder of DeckTherapeutics, Columbia University Professor, Dr. Richard Deckelbaum, discusses the technology he and co-workers invented for intravenous (acute) delivery of therapeutics based on omega-3 fatty acids. Oral omega-3s are a $40BN market globally and their benefits in preventing and treating